Detalhe da pesquisa
1.
Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Cancers (Basel)
; 15(7)2023 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37046648
2.
Cancer immune exclusion: breaking the barricade for a successful immunotherapy.
Front Oncol
; 13: 1135456, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37284199
3.
Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.
J Immunother Cancer
; 11(3)2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36889811
4.
Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Cell Death Dis
; 13(5): 447, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35534460
5.
Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy.
Cancers (Basel)
; 13(3)2021 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33540543
6.
Frontiers in cancer immunotherapy-a symposium report.
Ann N Y Acad Sci
; 1489(1): 30-47, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33184911
7.
Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer.
Front Oncol
; 10: 584, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32391269
8.
Blockade of Stat3 oncogene addiction induces cellular senescence and reveals a cell-nonautonomous activity suitable for cancer immunotherapy.
Oncoimmunology
; 9(1): 1715767, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32064174
9.
Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.
Cell Death Dis
; 14(12): 833, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38102106